trial

Lurasidone Extended Use Study

NCTId NCT01485640
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 162 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2014-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
162 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2011-06
Primary completion
2014-02
Eligibility
ALL

Interventions & indications

Drugs
Lurasidone

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Investigators

1
Medical Director, MDStudy Director

Sites

46 total
Kelowna, CanadaBarranquilla, ColombiaBello, ColombiaBogotá, ColombiaBrno-mesto, CzechiaOlomouc, CzechiaPrague, CzechiaPrague, CzechiaPrague, CzechiaOrvault, FranceToulun, FranceVisakhapatnam, India

Linked catalysts

1
Lurasidone Extended Use Study — primary completion2014-02

Facts & assertions

4 sourced
Enrollment
162
Phase
PHASE3
Primary Completion Date
2014-02
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Bipolar Disorder
indication
Bipolar Disorder
indication
investigator
Medical Director, MD
person